Funda Öztuna

Funda Öztuna

Auto-generated profile, based on publicly available information

Funda Öztuna

Chest Diseases, Karadeniz Technical University, Medical Faculty, Trabzon, Turkey

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2008 in Respiration
Verified
Journal Article
Closed access
PDF file
IUIrfan Ucgun
Irfan Ucgun
FOFunda Oztuna
Funda Oztuna
CDCanan Eren Dagli
Canan Eren Dagli
HYHuseyin Yildirim
Huseyin Yildirim
CBCengiz Bal
Cengiz Bal
Background: Exacerbation of chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality, but the effect of metabolic compensation of respiratory acidosis (RA) on mortality is not fully understood. Objective: To investigate the relationship between metabolic compensation and mortality in COPD patients with RA. Methods: We prospectively investigated all COPD patients with RA admitted to the respiratory intensive care unit between February 2001 and March 2007. Two hundred and thirteen patients (159 male, 54 female; mean age 65 ± 10.8 years) were divided into three groups (71 patients each) according to base excess (BE) levels: (1) low BE, (2) medium BE, and (3) high BE. H+ concentration was calculated according to their standard formula and BE was calculated according to the Van Slyke equation. Results: The overall mortality rate was 24.9%. The group mortality rates were 32, 17 and 25% in the low, medium and high BE groups, respectively (p = 0.001). When patients were divided into three groups according to the HCO3– levels, the group mortality rate was 59.1% in the low HCO3– group and 19.8% in the high HCO3– group. Based on univariate analysis, six factors affecting mortality were identified. However, multivariate analysis showed that the levels of serum HCO3– (p = 0.013; OR: 0.552; CI: 0.345–0.882) and creatinine (p = 0.019; OR: 2.114; CI: 1.132–3.949) had an independent effect. Conclusion: In patients with COPD exacerbation and hypercapnia, the development of sufficient metabolic compensation and adequate renal function significantly decreases mortality.

1 July 2022 in Turkish Thoracic Journal
Verified
Journal Article
Open access
OAOlcay Aycicek
Olcay Aycicek
YBYilmaz Bulbul
Yilmaz Bulbul
FOFunda Oztuna
Funda Oztuna
TOTevfik Ozlu
Tevfik Ozlu
SASelcuk Akkaya
Selcuk Akkaya
Sarcoidosis,mediastinal Lymphadenopathy,thorax computed tomography

25 March 2022 in Tuberk Toraks
Verified
Journal Article
Open access
OAOlcay Aycicek
Olcay Aycicek
MKMehtap Pehlivanlar Küçük
Mehtap Pehlivanlar Küçük
IKİlknur Koç
İlknur Koç
SMSevil Ayaydın Mürtezaoğlu
Sevil Ayaydın Mürtezaoğlu
APAyşegül Pehlivanlar
Ayşegül Pehlivanlar
TÖTevfik Özlü
Tevfik Özlü
Early isolation of the fungal pathogen and early initiation of treatment affect mortality and morbidity rates. The purpose of this study was to reveal the frequency of determination of fungal pathogens in bronchoscopy unit patients. The study was designed retrospectively. All patients who underwent bronchoscopy for any reason were enrolled. The patients with suspected fungal infection were divided into three groups after the procedure: 1) Proven fungal infection, 2) Colonization, 3) Without infection. One thousand one hundred and twenty-eight patients were included in the study. Fungal infection was suspected in 188 (16.7%) patients before bronchoscopy. After the examination of the bronchoscopic materials, it was determined that 59 (5.2%) patients had proven fungal infection, 148 (13.1%) patients had colonization, and 921 (81.7%) patients did not have fungal infection. The radiological findings of the patients that were indicative of fungal infection before bronchoscopy were observed as consolidation in 391 (34.7%) and nodule in 413 (36.6%). Fungal growth in bronchoscopic cultures was found in 186 (16.4%) patients, and the most common fungus was Candida albicans (C. albicans) in 110 (9.7%). The treatment was not changed according to the culture results in the patients. No treatment was initiated in the other 108 (98.2%) patients with C. albicans. One hundred and sixty-five (88%) of all fungal growths were detected in the BAL/bronchial lavage fluid. While 29 (45%) of them had not received antifungal treatment before, antifungal treatment was started after bronchoscopy. C. albicans was isolated the most among all bacterial and fungal agents in all patient groups that were immunosuppressed or not at a routine bronchoscopy unit. Diagnostic bronchoscopic sampling should be performed at the early stages of clinically or radiologically suspected fungal illness.

25 March 2022 in Tuberk Toraks
Verified
Journal Article
Closed access
AKAhmet Oğuzhan Küçük
Ahmet Oğuzhan Küçük
MKMehtap Pehlivanlar Küçük
Mehtap Pehlivanlar Küçük
APAyşegül Pehlivanlar
Ayşegül Pehlivanlar
SMSevil Ayaydın Mürtezaoğlu
Sevil Ayaydın Mürtezaoğlu
KÇKadir Çoban
Kadir Çoban
TÖTevfik Özlü
Tevfik Özlü
Introduction: This study aimed to evaluate the epidemiological, clinical, laboratory characteristics and treatment and clinical outcomes of severe COVID-19 cases from a 3rd degree intensive care unit in Turkey. Materials and Methods: The study was conducted in a level three, 16-bed COVID intensive care unit. The investigation was planned as a retrospective and observational study. Patients who were admitted with COVID-19 pneumonia and respiratory failure in the intensive care unit between March 2020 and March 2021 and followed up due to critical illness were evaluated. Results: A total of 213 patients that were admitted to the intensive care unit with the diagnosis of COVID-19 pneumonia were included in the study. Median age of the patients was 66 (IQR 56.5-74) years, and 134 (62.9%) were males. One hundred and sixty-six (77.9%) of the patients had at least one comorbidity. Patients were followed up mainly with invasive mechanical ventilation [104 (48.8%)] and high flow nasal cannula [67 (31.5%)]. Median number of days was 7 (IQR 4-10) and included the first symptom onset to intensive care admission. The time to intubation was 9 (IQR 4-15) days, and the median day to intensive care discharge was 16 (IQR 11-23). After the symptoms started, first tocilizumab 9 (IQR 5-11) and pulse steroid treatment 8 (IQR 3-11) were found to be close to each other. In total, 95 (44.6%) of the 213 patients died. Conclusion: SARS-CoV-2 associated viral disease can progress after simple symptoms to hospital admission in a median of four days and to intensive care admission requiring intubation in a median of nine days. We believe that a better understanding of the clinical course of COVID-19 and its change between centers can be revealed through sharing information from different countries and centers.

1 March 2023 in Medical Bulletin of Haseki
Verified
Journal Article
Closed access
OAOlcay Aycicek
Olcay Aycicek
AKAhmet Oguzhan Kucuk
Ahmet Oguzhan Kucuk
MKMehtap Pehlivanlar Kucuk
Mehtap Pehlivanlar Kucuk
MAMerve Ozdogan Algin
Merve Ozdogan Algin
APAysegul Pehlivanlar
Aysegul Pehlivanlar
FOFunda Oztuna
Funda Oztuna

1 January 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
MKMehtap Pehlivanlar Küçük
Mehtap Pehlivanlar Küçük
AKAhmet Oğuzhan Küçük
Ahmet Oğuzhan Küçük
APAyşegül Pehlivanlar
Ayşegül Pehlivanlar
SMSevil Ayaydın Mürtezaoğlu
Sevil Ayaydın Mürtezaoğlu
KÇKadir Çoban
Kadir Çoban
TÖTevfik Özlü
Tevfik Özlü
In this study, the efficacy of an IL-6 antagonist, Tocilizumab, administered in the early period was studied in intensive care patients with COVID-19 pneumonia followed by hypoxic and systemic inflammation not receiving mechanical ventilation support. Patients with COVID-19 pneumonia who have signs of hypoxia and systemic inflammation and/or who have acute bilateral infiltrates on chest radiograph and who received tocilizumab treatment were compared with the patients who received standard medical therapy. Patients who were followed up with COVID-19 pneumonia and respiratory failure between March 2020 and March 2021 were retrospectively evaluated in the study. A 400 mg - 800 mg iv dose (depending on weight) of Tocilizumab was administered. The primary endpoint was determined as intensive care unit mortality. A total of 213 patients who were admitted with respiratory failure associated with COVID-19 to our third-level intensive care unit were evaluated. Of these patients, the study was conducted with 50 patients in the tocilizumab treatment group and 92 patients in the standard treatment group. During the intensive care period, 26 patients (28.3%) in the standard treatment group and 12 patients (24%) in the group receiving tocilizumab died. The adjusted hazard ratio for mortality in the tocilizumab group was 0.39 (95% confidence interval [CI], 0.186 to 0.808; p = 0.001 by log-rank test). During the intensive care period, 22 patients (24.8%) in the standart treatment group and 16 patients (32%) in the tocilizumab group were intubated. The adjusted hazard ratio for a primary outcome intubation in the tocilizumab group was 0.71 (95% confidence interval [CI], 0.355 to 1.424; p = 0.184 by log-rank test).